Inclusivity of patients in early phase breast cancer clinical trials☆

被引:0
|
作者
Sinha, A. [1 ]
Barwell, L. [1 ]
Jeffery, H. [1 ,2 ]
Peterson, Z. [1 ,2 ]
Shifa, B. [1 ,2 ]
Attia, M. [2 ,3 ]
Badawy, K. [1 ]
Purushotham, A. [1 ,2 ]
机构
[1] Kings Coll London, London, England
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] Cairo Univ, Fac Med, Dept Gen Surg, Cairo, Egypt
来源
JOURNAL OF CANCER POLICY | 2024年 / 41卷
关键词
Diversity; Clinical Trials; Recruitment; Ethnicity; UNDER-REPRESENTATION; STREPTOMYCIN;
D O I
10.1016/j.jcpo.2024.100494
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Studies have shown that certain groups of patients are underrepresented in clinical trials including non-Caucasian ethnicity, poor fluency in English, low socioeconomic status, older age, neurodivergence, and large Body Mass Index (BMI). There is a need to ensure adequate representation of these groups so that the results of any trial accurately reflect the population. The aim of this study was to review the pathway of patients recruited into two early phase breast cancer clinical and determine the inclusivity of patients from the aforementioned sub-groups. Methods: The Breast Cancer Research Database was reviewed, and the characteristics of all patients who were screened for eligibility in two early phase clinical trials was examined. The English Indices of Deprivation was used to populate the Index of Multiple Deprivation (IMD) for each patient using their postcode. Results: In total, 392 patients were eligible to participate, between September 2020 to May 2023. Of these, 144 (36.7 %) were recruited to these two trials. In all, 100 % of patients eligible for these trials were approached and screened for participation. Eligible patients had a mean age of 53.5 years. Recruited patients were younger on average than those not recruited (49.1 years vs 56.0 years, p<0.0001). Only one recruited patient required an interpreter, compared with 24 (9.7 %%) of those who were not recruited (p<0.001). There was no difference in the IMD (p=0.38), BMI (p=0.34) and neurodiversity (p=0.10) between patients recruited into clinical trials and those who were not. Conclusion: Older age and poor fluency in the English language remain barriers to participation in early-phase clinical trials despite implementing a clear pathway to trial recruitment. There is a pressing need to address these barriers by raising awareness, improve appropriate training and providing comprehensive trial information to patients in the language of their choice.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] An evaluation of the psychological impact of early phase clinical trials in cancer patients
    Jittla, P.
    Graham, D.
    Zhou, C.
    Halliwell, J.
    O'Reilly, S.
    Aruketty, S.
    Azizi, A.
    Germetaki, T.
    Lowe, J.
    Little, M.
    Punnett, G.
    McMahon, P.
    Benson, L.
    Carter, L.
    Krebs, M. G.
    Thistlethwaite, F.
    Yorke, J.
    Cook, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1097 - S1098
  • [2] Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
    Criscitiello, Carmen
    Marra, Antonio
    Morganti, Stefania
    Zagami, Paola
    Gandini, Sara
    Esposito, Angela
    Curigliano, Giuseppe
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 157 : 40 - 49
  • [3] The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer
    Brennan, Meghan
    Gass, Paul
    Haeberle, Lothar
    Wang, Daidong
    Hartmann, Arndt
    Lux, Michael P.
    Beckmann, Matthias W.
    Untch, Michael
    Fasching, Peter A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 747 - 758
  • [4] The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer
    Meghan Brennan
    Paul Gass
    Lothar Häberle
    Daidong Wang
    Arndt Hartmann
    Michael P. Lux
    Matthias W. Beckmann
    Michael Untch
    Peter A. Fasching
    [J]. Breast Cancer Research and Treatment, 2018, 171 : 747 - 758
  • [5] The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer
    Brennan, M. B.
    Wang, D.
    Gass, P.
    Hein, A.
    Beckmann, M. W.
    Fasching, P. A.
    [J]. CANCER RESEARCH, 2017, 77
  • [6] Patients' Perceptions On Breast Cancer Clinical Trials
    Pittens, C. A. C. M.
    Elberse, J. E.
    Tax, S.
    van Leeuwen-Stok, A. E.
    Schrieks, M.
    Jonker, M.
    Broerse, J. E. W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S50 - S50
  • [7] Patients' perceptions on breast cancer clinical trials
    Tax, S.
    Elberse, J.
    Pittens, C.
    Broerse, J.
    Van Leeuwen-Stok, A.
    Schrieks, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S446 - S446
  • [8] Current phase III breast cancer clinical trials
    不详
    [J]. ONCOLOGY-NEW YORK, 2006, 20 (07): : 696 - +
  • [9] Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
    Weiss, Jennifer A.
    Nicklawsky, Andrew
    Kagihara, Jodi A.
    Gao, Dexiang
    Fisher, Christine
    Elias, Anthony
    Borges, Virginia F.
    Kabos, Peter
    Davis, Sarah L.
    Leong, Stephen
    Eckhardt, Sue Gail
    Diamond, Jennifer R.
    [J]. CANCER MEDICINE, 2020, 9 (23): : 8801 - 8808
  • [10] Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials
    George, Angela
    Kristeleit, Rebecca
    Rafii, Saeed
    Michie, Caroline O.
    Bowen, Rebecca
    Michalarea, Vasiliki
    van Hagen, Tom
    Wong, Mabel
    Rallis, Grigorios
    Molife, L. Rhoda
    Lopez, Juanita
    Banerji, Udai
    Banerjee, Susana N.
    Gore, Martin E.
    de Bono, Johann S.
    Kaye, Stan B.
    Yap, Timothy A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 76 : 52 - 59